Skip to main content

DICE Therapeutics, Inc. (DICE)

NASDAQ: DICE · Delayed Price · USD
34.14 -1.35 (-3.80%)
Sep 21, 2021 4:00 PM EDT - Market closed
Market Cap1.24B
Revenue (ttm)1.54M
Net Income (ttm)-28.58M
Shares Out36.32M
EPS (ttm)-0.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,464,683
Open-
Previous Close35.49
Day's Range33.87 - 36.61
52-Week Range0.00 - 36.61
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About DICE

DICE Therapeutics is a biopharmaceutical company leveraging our proprietary DELSCAPE platform to design and develop a pipeline of wholly-owned oral small molecule therapeutics against validated biologic targets to address chronic diseases in immunology and other therapeutic areas. In collaboration with Sanofi, we are also developing a therapeutic candidate for immuno-oncology indications. We believe there is a significant unmet medical need for convenient oral therapies in chronic immunological diseases that offer the therapeutic benefits of sy...

IndustryBiotechnology
IPO DateSep 15, 2021
CEOJ. Kevin Judice, Ph.D.
Employees32
Stock ExchangeNASDAQ
Ticker SymbolDICE
Full Company Profile

Financial Performance

In 2020, DICE's revenue was $863,000, a decrease of -85.06% compared to the previous year's $5.78 million. Losses were -$23.74 million, 83.5% more than in 2019.

Financial Statements

News

DICE Therapeutics Announces Pricing of Upsized Initial Public Offering

DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its...

6 days ago - GlobeNewswire

DICE Therapeutics IPO Registration Document (S-1)

DICE Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 weeks ago - SEC

DiCE Molecules Announces $60 Million Series C-1 Financing

DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, today ...

4 weeks ago - Business Wire